Xiao Yilei, Zhang Lina, Song Zikun, Guo Chuanjun, Zhu Jianxin, Li Zhongmin, Zhu Shugan
Department of Neurosurgery, Qilu Hospital of Shandong University, Jinan, Shandong, China (mainland).
Department of Intensive Care Medicine, Liaocheng People's Hospital, Liaocheng, Shandong, China (mainland).
Med Sci Monit. 2016 Mar 15;22:855-62. doi: 10.12659/msm.897164.
Previous studies showed the aberrant expression of microRNA-182 (miR-182) in glioma tissue. However, the exact role of circulating miR-182 in glioma remains unclear. Here, we confirmed the expression of plasma circulating miR-182 in glioma patients, and further explored its potential diagnostic and prognostic value.
MATERIAL/METHODS: Real-time quantitative PCR (RT-PCR) was used to measure circulating cell-free miR-182 from 112 glioma patients and 54 healthy controls.
Our findings showed that the level of circulating miR-182 in glioma patients was higher than that in healthy controls (P<0.001), which was significantly associated with KPS score (P=0.025) and WHO grade (P<0.001). The area under the receiver operating characteristic (ROC) curve (AUC) was 0.778. The optimal cut-off value was 1.56, and the sensitivity and specificity were 58.5% and 85.2%, respectively. Interestingly, a high predictive value of circulating miR-182 was observed in high-grade glioma (AUC=0.815). However, the AUC was lower in low-grade glioma (AUC=0.621). Kaplan-Meier analysis demonstrated that the cumulative 5-year overall survival rate in the high miR-182 group was significantly lower than that in the low miR-182 group in both overall survival (OS) (P=0.003) and disease-free survival (DFS) (P=0.006). Moreover, multivariate Cox analysis revealed that circulating miR-182 was an independent prognostic indicator for OS (P=0.034) and DFS (P=0.013).
These results suggest that circulating miR-182 may be a potential noninvasive biomarker for the diagnosis and prognosis of human glioma.
先前的研究表明，微小RNA-182（miR-182）在胶质瘤组织中存在异常表达。然而，循环miR-182在胶质瘤中的确切作用仍不清楚。在此，我们证实了胶质瘤患者血浆中循环miR-182的表达，并进一步探讨了其潜在的诊断和预后价值。
材料/方法：采用实时定量聚合酶链反应（RT-PCR）检测112例胶质瘤患者和54例健康对照者血浆中游离循环miR-182的水平。
我们的研究结果显示，胶质瘤患者循环miR-182水平高于健康对照者（P<0.001），这与KPS评分（P=0.025）和世界卫生组织（WHO）分级（P<0.001）显著相关。受试者操作特征（ROC）曲线下面积（AUC）为0.778。最佳截断值为1.56，敏感性和特异性分别为58.5%和85.2%。有趣的是，在高级别胶质瘤中观察到循环miR-182具有较高的预测价值（AUC=0.815）。然而，在低级别胶质瘤中AUC较低（AUC=0.621）。Kaplan-Meier分析表明，在总生存期（OS）（P=0.003）和无病生存期（DFS）（P=0.006）方面，高miR-182组的5年累积总生存率显著低于低miR-182组。此外，多因素Cox分析显示，循环miR-182是OS（P=0.034）和DFS（P=0.013）的独立预后指标。
这些结果表明，循环miR-182可能是人类胶质瘤诊断和预后的潜在无创生物标志物。
